We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Stem Cells Heal Hearts Years Later

By HospiMedica staff writers
Posted on 09 Nov 2005
Up to eight years following a heart attack, bone marrow stem cells from patients with heart muscle damage were still able to increase the function and exercise capacity of the patients, according to a new study.

The study is the first to use stem cell infusions to treat heart patients many months or years after a heart attack. More...
Researchers at the Heinrich-Heine University in Dusseldorf (Germany) harvested bone marrow from the hip bones of the patients to avoid transplant rejection. After being processed, stem cells from the marrow were infused through a catheter into the coronary artery where the heart attack occurred.

"The main results were at least threefold: an improvement in global left ventricular function by 15%, infarction wall movement velocity rose 57%, and there was a significant reduction of infarct size by 30%,” noted Bodo E. Strauer, M.D., of Heinrich-Heine University, who led the trial.

If further trials produce similar results, this treatment may not only reverse some heart attack damage and improve symptoms and daily functioning but might also reduce the risk of heart failure, according to Dr. Strauer. Current interventions such as clot-busting drugs and angioplasty cannot restore damaged heart tissue. Earlier studies on the use of stem cells soon after a heart attack also demonstrated healing and improved function.

"The stem cell therapy demonstrates that restoration is possible, clinically feasible, and associated with an improvement in the performance of the heart by approximately 20-30%,” said Dr. Strauer. "This therapy is safe, similar to an ‘own blood injection or transfusion,' and has no side effects.” He noted, however, that the current trial involved only 18 patients and more research is needed.

The trial results were reported in the November 1, 2005, issue of the Journal of the American College of Cardiology.




Related Links:
Heinrich-Heine U.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.